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Abstract
Background
Polygenic risk scores (PRSs) can stratify populations into cardiovascular disease (CVD) risk
groups. We aimed to quantify the potential advantage of adding information on PRSs to con-
ventional risk factors in the primary prevention of CVD.
Methods and findings
Using data from UK Biobank on 306,654 individuals without a history of CVD and not on
lipid-lowering treatments (mean age [SD]: 56.0 [8.0] years; females: 57%; median follow-up:
8.1 years), we calculated measures of risk discrimination and reclassification upon addition
of PRSs to risk factors in a conventional risk prediction model (i.e., age, sex, systolic blood
pressure, smoking status, history of diabetes, and total and high-density lipoprotein choles-
terol). We then modelled the implications of initiating guideline-recommended statin therapy
in a primary care setting using incidence rates from 2.1 million individuals from the Clinical
Practice Research Datalink. The C-index, a measure of risk discrimination, was 0.710 (95%
CI 0.703–0.717) for a CVD prediction model containing conventional risk predictors alone.
Addition of information on PRSs increased the C-index by 0.012 (95% CI 0.009–0.015), and
resulted in continuous net reclassification improvements of about 10% and 12% in cases
and non-cases, respectively. If a PRS were assessed in the entire UK primary care popula-
tion aged 40–75 years, assuming that statin therapy would be initiated in accordance with
the UK National Institute for Health and Care Excellence guidelines (i.e., for persons with a
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predicted risk of�10% and for those with certain other risk factors, such as diabetes, irre-
spective of their 10-year predicted risk), then it could help prevent 1 additional CVD event
for approximately every 5,750 individuals screened. By contrast, targeted assessment only
among people at intermediate (i.e., 5% to <10%) 10-year CVD risk could help prevent 1
additional CVD event for approximately every 340 individuals screened. Such a targeted
strategy could help prevent 7% more CVD events than conventional risk prediction alone.
Potential gains afforded by assessment of PRSs on top of conventional risk factors would
be about 1.5-fold greater than those provided by assessment of C-reactive protein, a plasma
biomarker included in some risk prediction guidelines. Potential limitations of this study
include its restriction to European ancestry participants and a lack of health economic
evaluation.
Conclusions
Our results suggest that addition of PRSs to conventional risk factors can modestly enhance
prediction of first-onset CVD and could translate into population health benefits if used at
scale.
Author summary
Why was this study done?
• Application of polygenic risk scores (PRSs) has opened opportunities to enhance risk
stratification and prevention for common diseases. The clinical utility of PRSs in cardio-
vascular disease (CVD) risk prediction is, however, uncertain.
• Previous analyses have generally focused only on coronary heart disease (CHD) rather
than the composite outcome of CHD and stroke, and have often lacked modelling of
clinical implications of initiating guideline-recommended interventions (e.g., statin
therapy).
What did the researchers do and find?
• We quantified the incremental predictive gain with PRSs on top of conventional risk
factors using data on 306,654 individuals from UK Biobank.
• We modelled the population health implications of initiating statin therapy as recom-
mended by current guidelines using data from 2.1 million individuals from the Clinical
Practice Research Datalink.
• Addition of information on PRSs to a conventional risk prediction model increased the
C-index (a measure of risk discrimination) and improved risk classification of cases and
non-cases.
• We estimated that targeted assessment of PRSs among people at intermediate (i.e., 5%
to<10%) 10-year CVD risk could help prevent 1 additional CVD event for
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approximately every 340 individuals screened, which would be almost 15 times more
efficient than blanket assessment of PRS.
What do these findings mean?
• Addition of PRSs to conventional risk factors provided modest improvement in predic-
tion of first-onset CVD.
• Nevertheless, these moderate improvements could translate into meaningful clinical
benefit if applied at scale, and lead to the prevention of 7% more CVD events than con-
ventional risk factors alone.
• Our results also suggest that targeted use of PRSs would be more efficient than blanket
population-wide use.
• Future studies should seek to evaluate PRSs in non-European ancestry populations, and
perform formal health economic evaluations.
Introduction
Advances in the application of polygenic risk scores (PRSs) have opened opportunities to
enhance disease risk prediction by stratifying populations into risk groups using information
on millions of variants across the genome [1–4]. The UK government’s Department of Health
and Social Care green paper on disease prevention has stated: ‘As the evidence develops, com-
plementing existing risk scores. . .with this kind of genetic information [i.e., PRSs] will be a
priority for the UK healthcare system’ [5]. The US Centers for Disease Control and Prevention
and the US National Institutes of Health are also considering the value of integrating PRSs
into clinical practice [6].
A key strategy in the primary prevention of cardiovascular disease (CVD) is the use of risk
prediction algorithms to target preventive interventions to people who may benefit from them
most [7–12]. These algorithms typically include information on conventional risk factors,
including age, sex, smoking history, history of diabetes, blood pressure, total cholesterol, and
high-density lipoprotein (HDL) cholesterol [8–10]. The population health utility of PRSs in
CVD risk prediction is, however, uncertain. Previous analyses have generally focused only on
coronary heart disease (CHD) rather than the composite outcome of CHD and stroke, even
though the composite outcome is the focus of most primary prevention guidelines. Further-
more, most previous PRS studies have lacked modelling of the clinical implications of initiat-
ing guideline-recommended interventions (e.g., statin therapy) [13,14], meaning that it has
been difficult to judge the potential clinical gains of assessing PRSs.
Our study, therefore, aimed to address 2 questions. First, what is the improvement in CVD
risk prediction when PRSs are added to risk factors used in conventional risk algorithms? We
analysed 306,654 participants from UK Biobank (UKB) to assess the value of adding PRSs to
several conventional risk factors. Second, what is the estimated population health impact of
using information on PRSs for CVD prediction? We modelled data from 2.1 million individu-
als in the Clinical Practice Research Datalink (CPRD) to estimate the benefit of initiating statin
therapy as recommended by guidelines. To contextualise our findings, we compared the
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incremental predictive gains afforded by PRSs with that provided by C-reactive protein (CRP),
a plasma biomarker recommended for risk prediction in some CVD primary prevention
guidelines [12,15].
Methods
Study design and overview
Our study involved several interrelated components (Fig 1). First, we constructed separate
PRSs for CHD and stroke, using methods previously described [16,17]. Second, we calculated
measures of risk discrimination and reclassification to quantify the incremental predictive
gain with these PRSs on top of conventional risk factors. Third, to estimate the potential for
disease prevention in a general population setting, we adapted (i.e., recalibrated) our findings
to the context of a primary prevention population eligible for CVD screening, using incidence
rates from contemporary computerised records from general practices in the UK. Fourth, we
modelled the clinical implications of initiating statin therapy as recommended by current
guidelines, comparing a ‘blanket’ approach (i.e., assessment of PRSs in all individuals eligible
for CVD primary prevention) with a ‘targeted’ approach (i.e., focusing PRSs assessment only
in people judged to be at intermediate 10-year risk of CVD after initial screening with conven-
tional risk predictors alone). Fifth, to help contextualise the potential population health gains
Fig 1. Study design and overview. CHD, coronary heart disease; PRS, polygenic risk score.
https://doi.org/10.1371/journal.pmed.1003498.g001
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afforded by assessing PRSs, we compared them in the same dataset with gains afforded by
assessment of CRP.
Ethics statement
This research has been conducted using the UKB resource under application number 26865.
The UKB study was approved by the North West Multi-centre Research Ethics Committee,
and all participants provided written informed consent to participate in the UKB. This study is
based in part on data from the CPRD obtained under licence from the UK Medicines and
Healthcare products Regulatory Agency (protocol number 162RMn2). The data are provided
by patients and collected by the National Health Service as part of their care and support.
Data sources
UK Biobank prospective study. Details of the design, methods, and participants of UKB
have been described previously [18,19]. Briefly, participants aged 40 to 75 years identified
through primary care lists were recruited across 22 assessment centres throughout the UK
between 2006 and 2010. At recruitment, information was collected via a standardised ques-
tionnaire and selected physical measurements. Details of the data used from UKB are provided
in S1 Text. Data were subsequently linked to Hospital Episode Statistics (HES), as well as
national death and cancer registries. HES uses the International Classification of Diseases
(ICD) 9th and 10th revisions to record diagnosis information, and the Office of Population,
Censuses and Surveys: Classification of Interventions and Procedures, version 4 (OPCS-4), to
code operative procedures. Death registries include deaths in the UK, with both primary and
contributory causes of death coded according to ICD-10.
Genotyping was undertaken using a custom-built genome-wide array of approximately
826,000 markers [18,20]. Imputation to approximately 96 million markers was subsequently
carried out using the Haplotype Reference Consortium and UK10K/1000 Genomes reference
panels [20]. Clinical biochemistry markers, including total cholesterol, HDL cholesterol, and
CRP, were measured at baseline in serum samples. Full details of the biochemistry sampling,
handling and quality control protocol, and assay method have been provided previously [21].
UK Clinical Practice Research Datalink. To estimate the potential for disease prevention
in a general population setting, we used data from the CPRD, a primary care database of anon-
ymised medical records covering over 11.3 million individuals opting into data linkage from
674 general practices in the UK [22]. Individual-level data from consenting practices in the
CPRD have been linked to HES and the national death registry. Details of the CPRD data used
and endpoint definition are provided in S2 Text. The present analysis involved records of 2.1
million patients, a random sample of all CPRD data, working under the assumption that indi-
viduals in this database should be broadly representative of the UK general population.
Statistical analysis
To approximate populations relevant to CVD primary prevention, we focused on first-onset
CVD outcomes among those with no prior history of CVD and not taking lipid-lowering treat-
ments at recruitment. Analyses were performed according to a pre-specified analysis plan (S1
Analysis Plan) and restricted to participants of self-reported European ancestry, excluding
those who (1) had missing genotype array or conventional risk factor information; (2) had a
history of CVD at baseline (i.e., CHD, other heart disease, stroke, transient ischaemic attack,
peripheral vascular disease, angina, or cardiovascular revascularization); (3) used lipid-lower-
ing treatment at baseline; or (4) were included in the dataset to estimate component score mix-
ing weights during PRS construction (see S1 Fig). The primary outcome was a first-onset CVD
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event, defined as the composite of CHD (i.e., myocardial infarction or fatal CHD) or any
stroke. Secondary outcomes included each of CHD and stroke separately, and a combination
of CHD, stroke, and cardiac revascularisation procedures (i.e., percutaneous transluminal cor-
onary angioplasty [PTCA] and coronary artery bypass grafting [CABG]) (S1 Table).
We used separate PRSs for CHD and ischaemic stroke as 2 independent variables to predict
the composite CVD outcome. PRSs were previously constructed using a meta-score approach
based on external summary statistics from the previous largest genome-wide association stud-
ies (GWASs) of CHD and stroke [23,24]. Detailed information on PRS derivation has been
previously provided [16,17], and the PRSs are publicly available and annotated at the PGS Cat-
alog (http://www.pgscatalog.org) under accessions PGS000018 and PGS000039, respectively.
The PRS for CHD comprised 1,743,979 variants where the mixing weights of component
scores were estimated using 3,000 participants in UKB. The PRS for ischaemic stroke included
2,759,740 variants where the mixing weights of component scores were estimated using 12,000
participants in UKB (including the 3,000 participants mentioned above). Participants used in
the training dataset were excluded from subsequent analysis. Previous analyses have not found
evidence of overfitting [16,17], and independent replications have demonstrated consistent
effect sizes [25–27]. The partial Pearson correlation coefficient between the PRS for CHD and
the PRS for stroke was 0.32. In sensitivity analyses we (1) replaced the PRS for ischaemic stroke
with a PRS for all stroke and (2) used a single PRS for the composite CVD outcome.
HRs were calculated using Cox proportional hazards models, stratified by UKB recruitment
centre and sex, and using time since study entry as the timescale. Outcomes were censored if a
participant was lost to follow-up or died from non-CVD causes, or if the end of available fol-
low-up was reached (for England: 31 March 2017; Scotland: 30 October 2016; Wales: 30 May
2016). Predictors were entered as linear terms, after visual checking for log-linearity. No viola-
tion of the proportional hazards assumption was identified. Sensitivity analyses included calcu-
lation of cumulative incidence of CVD outcomes based on the cause-specific hazards
estimated from Cox regression, in the presence of competing risk from non-CVD deaths
[28,29].
The incremental predictive ability of PRSs for CHD and stroke was assessed upon addition
(as 2 separate linear terms) to a model containing age, sex, systolic blood pressure, smoking
status, history of diabetes, and total and HDL cholesterol (i.e., conventional risk factors). Risk
discrimination was assessed using Harrell’s C-index, stratified by UKB recruitment centre and
sex [30]. To avoid overestimation of the model’s ability to predict risk, we applied an internal/
external validation approach by validating within a subset (i.e., 1 study centre or a 10% ran-
domly selected population in UKB) the prediction model derived from the remaining datasets.
Results were then meta-analysed across all validation subsets, weighted by the number of
events in that specific subset. Improvements in risk prediction were also quantified by the net
reclassification index (NRI), which summarises appropriate directional change in risk predic-
tions for those who do and do not experience an event during follow-up (with increases in pre-
dicted risk being appropriate for cases and decreases being appropriate for non-cases) [31,32].
Calibration was assessed by comparing the observed and predicted risks across deciles of pre-
dicted risk, and by calculating calibration slope, root mean square error, and the Greenwood–
Nam–D’Agostino p-value [13,14,33] using a 10-fold cross-validation approach to avoid
optimism.
To assess the population health relevance of adding PRSs to conventional risk factors, we
generalised our reclassification analyses to the context of a UK population eligible for primary
prevention screening (S3 Text). Using CPRD data we recalibrated risk prediction models
derived in UKB to give 10-year risks that would be expected in such a UK primary care setting,
employing methods previously described [34]. (Since 10 years of follow-up was not available
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for all UKB recruitment centres, we used 9-year risk estimates in reclassification analyses.)
Details are provided in S3 Text.
We modelled a population of 100,000 adults aged 40–75 years in the CPRD, with an age
and sex profile matching that of the contemporary UK population (2017 mid-year population)
[35], and CVD incidence rates as observed in individuals without previous CVD and not tak-
ing statins. We assumed an initial policy of statin allocation for people at�10% predicted
10-year risk as recommended by National Institute for Health and Care Excellence (NICE)
guidelines [7]. We then modelled additional targeted assessment of PRSs, or CRP, among peo-
ple at intermediate risk (5% to<10% predicted 10-year risk) to estimate the potential for addi-
tional treatment allocation and case prevention, assuming statin allocation would reduce CVD
risk by 20% [36]. Details are in S3 Text. Analyses were performed with PLINK 2.0 [37] and
Stata version 14, with 2-sided p-values and 95% confidence intervals. This study follows TRI-
POD reporting guidelines (S1 TRIPOD Checklist).
Results
Characteristics of the study participants and association with CVD
outcomes
Of the 502,219 participants initially enrolled in UKB, 306,654 participants met the inclusion
criteria for this analysis: self-reported European ancestry, without a history of CVD, not on
lipid-lowering treatment, and with complete information on genotype array data and conven-
tional risk predictors (Table 1). During 2.6 million person-years at risk (median [5th, 95th per-
centile] follow-up of 8.1 [6.8–9.4] years), 5,680 CVD cases were recorded, including 3,333
CHD and 2,347 stroke events. Fig 2 shows the baseline characteristics of participants, as well as
HRs for CVD adjusted for conventional risk factors. HRs for CHD and stroke outcomes sepa-
rately and for the composite secondary outcome (including CHD, stroke, PTCA, and CABG)
are presented in S2 Fig. Both PRSs showed log-linear associations with CVD outcomes, with
Table 1. Baseline characteristics of UK Biobank participants who had no prior history of vascular disease and
were not on lipid-lowering treatment, by sex (n = 306,654).
Baseline characteristic Female Male Total
Number of participants 174,773 131,881 306,654
Age at recruitment, years 56.0 (7.9) 55.9 (8.2) 56.0 (8.0)
Cardiovascular risk factors
Current-smoker, percent 9.3 11.7 10.3
History of diabetes, percent 0.8 1.7 1.2
Treatment of hypertension, percent 10.9 11.7 11.2
Systolic blood pressure, mm Hg 134.2 (18.6) 140.4 (17.3) 136.9 (19.1)
Total cholesterol, mmol/l 6.0 (1.1) 5.8 (1.0) 5.9 (1.1)
HDL cholesterol, mmol/l 1.6 (0.4) 1.3 (0.3) 1.5 (0.4)
LDL cholesterol, mmol/l 3.7 (0.8) 3.7 (0.8) 3.7 (0.8)
C-reactive protein, Ln, mg/l 0.3 (1.1) 0.3 (1.0) 0.3 (1.1)
Incident cardiovascular outcomes
Follow-up, years, median (5th–95th percentile) 8.2 (6.8–9.4) 8.1 (6.5–9.3) 8.1 (6.8–9.4)
Number of coronary heart disease cases 2,453 880 3,333
Number of stroke cases 1,311 1,036 2,347
Data are shown as mean (SD), unless otherwise stated, adjusted for UK Biobank study centre.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003498.t001
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HRs of 1.57 (95% CI 1.51–1.62) for CHD and 1.19 (95% CI 1.14–1.24) for stroke, after adjust-
ment for age only (S3 Fig). HRs per 1-SD higher PRS did not materially change after adjust-
ment for conventional risk factors; HRs were similar across people with different levels of risk
factors, including family history of CVD (S4 and S5 Figs).
Incremental value in risk prediction
We assessed the incremental predictive ability of PRSs using measures of risk discrimination
and reclassification, adding PRSs for CHD and stroke as 2 independent linear terms to a
model containing conventional CVD risk factors. For the CVD outcome, the C-index was
0.710 (95% CI 0.703–0.717) for a prediction model containing conventional risk factors alone.
The addition of information on PRSs increased the C-index by 0.012 (95% CI 0.009–0.015; Fig
3), yielding a continuous NRI of 10.2% (95% CI 7.2%–13.2%) among CVD cases and 12.6%
(95% CI 12.2%–13.0%) among non-cases (Table 2). By comparison, the C-index increased by
0.004 (95% CI 0.003–0.006; Fig 3) after adding information on CRP to the conventional
model. The improvement in NRI was also less with addition of CRP than with addition of
PRSs, with incident cases more often correctly increased in risk by addition of PRSs (Table 2).
Models including PRSs showed good calibration, with good agreement between the observed
and predicted CVD risks (S6 Fig).
In hypothesis-generating analyses, the C-index changes with PRSs were possibly somewhat
higher in men than women, and in participants with higher total cholesterol, lower HDL
Fig 2. Adjusted hazard ratios of conventional cardiovascular risk factors and polygenic risk scores for first-onset
cardiovascular outcomes. Hazard ratios (HRs) were estimated using Cox regression, stratified by study centre and sex,
and adjusted for age at baseline, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-
density lipoprotein (HDL) cholesterol levels, where appropriate. For continuous variables, HRs are shown per SD
higher of each predictor to facilitate comparison. For categorical variables, HRs are shown for men versus women, for
patients with diabetes versus without, and for current smokers versus others.
https://doi.org/10.1371/journal.pmed.1003498.g002
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cholesterol, and higher predicted 10-year CVD risk (Fig 4; S2 Table). Among CVD cases and
controls, continuous NRIs with assessment of PRSs were 11.5% (95% CI 7.8%–15.1%) and
14.1% (95% CI 13.5%–14.6%) in men, and 8.3% (95% CI 3.1%–13.5%) and 8.8% (95% CI
8.3%–9.3%) in women, respectively (S3 Table). The predictive value of PRSs was greater for
CHD than for stroke outcomes (Table 2; Fig 3 and S7 Fig).
Fig 3. Incremental predictive ability of polygenic risk scores and C-reactive protein for cardiovascular disease, above
conventional risk factors. Conventional risk factors included age at baseline, sex, smoking status, history of diabetes,
systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. C-index and related changes were
estimated using Cox regression, stratified by study centre and sex, adjusted for age at baseline, smoking status, history of
diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. 95% confidence intervals (CIs)
were estimated using the efficient jackknife approach.
https://doi.org/10.1371/journal.pmed.1003498.g003
Table 2. Net reclassification index (NRI) for cardiovascular disease (generalised to a primary prevention population) with addition of information on polygenic
risk scores or C-reactive protein, above conventional risk factors.







Conventional risk factors plus polygenic risk scores
Non-cases 12.6 (12.2, 13.0) 17.5 (17.1, 17.9) 6.6 (6.2, 7.0)
Cases 10.2 (7.2, 13.2) 14.6 (10.8, 18.4) 3.5 (−1.2, 8.2)
Conventional risk factors plus C-reactive protein
Non-cases 12.0 (11.6, 12.4) 12.6 (12.2, 13.0) 9.9 (9.5, 10.2)
Cases 2.1 (−1.1, 4.9) 3.8 (0.1, 7.6) 0.8 (−4.0, 5.5)
Conventional risk factors included age at baseline, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein
cholesterol, with stratification by study centre and sex, where appropriate.
https://doi.org/10.1371/journal.pmed.1003498.t002
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The results of adding information on PRSs were broadly similar to those observed overall
in analyses that included (1) information on body-mass index, family history of CVD, use of
blood-pressure-lowering treatment, or CRP in the prediction model (S4 Table; S8 Fig); (2) par-
ticipants receiving lipid-lowering treatment at baseline (S5 Table; S9 Fig); (3) use of PRSs
Fig 4. Incremental predictive ability of polygenic risk scores (PRSs) for cardiovascular disease (CVD) outcomes, beyond conventional risk
predictors, across different baseline population characteristics. The base model included information on the conventional risk factors, i.e., age at
baseline, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein (HDL) cholesterol, with
stratification by study centre and sex, where appropriate. The prediction model within each subgroup was constructed using coefficients estimated
among the entire population.
https://doi.org/10.1371/journal.pmed.1003498.g004
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derived for the composite CVD outcome or for all stroke (S6 Table); and (4) a broader defini-
tion of the CVD outcome (i.e., CHD, stroke, PTCA, or CABG; S9 Fig). Furthermore, similar
results were observed in analyses using the internal/external cross-validation approach (S10
and S11 Figs), the Pooled Cohort Equations (S7 Table), or competing risk models for non-
CVD deaths (S8 Table).
Estimate of the potential for disease prevention
In population health modelling, we used age- and sex-specific incidence data from 2.1 million
individuals in the CPRD without previous CVD and not taking statins to recalibrate risk mod-
els and achieve a predicted risk distribution as would be expected in this primary care popula-
tion (S3 Text). We translated age- and sex-specific targeted assessment of PRSs to a population
of 100,000 adults aged 40–75 years, assuming the age and sex structure of the current UK pop-
ulation, and CVD incidence rates observed in UK primary care. Under this scenario, we esti-
mated that, using conventional risk factors alone, there would be 23,973 individuals classified
as having intermediate 10-year (i.e., 5% to<10%) risk who were not already taking or eligible
for statin treatment (i.e., people without a history of diabetes or CVD, and with low-density
lipoprotein (LDL) cholesterol < 5.0 mmol/l; Fig 5). Additional assessment of PRSs in these
individuals (i.e., a ‘targeted’ approach focusing only in people judged to be at intermediate
10-year risk of CVD after initial screening with conventional risk factors alone) would reclas-
sify 3,115 intermediate-risk individuals as high-risk (i.e.,�10%), of whom approximately 357
would be expected to have a CVD event within 10 years. This would correspond to an increase
of about 7.1% (357/5,054) of the CVD events already classified at high risk using conventional
risk predictors alone.
Assuming statin allocation per current guidelines (i.e., those with 10-year CVD risk� 10%)
and statin treatment conferring a 20% relative risk reduction, such targeted assessment of
PRSs among the intermediate-risk group would help prevent 72 (i.e., 357 × 0.2) events over
the next 10-year period. In other words, targeted assessment of PRSs in individuals at interme-
diate risk for a CVD event could help prevent 1 additional event over 10 years for every 336
people so screened. For comparison, the number needed to screen with targeted assessment of
CRP would be 491 (S9 Table). Similar results were observed when analysis involved cutoffs for
clinical risk categories defined by other guidelines (S10 Table; S12 Fig).
In contrast with the targeted approach, we also modelled a blanket population-wide strategy
of additional assessment of PRSs in all adults aged 40–75 years eligible for CVD primary pre-
vention. In this scenario, compared to using conventional risk factors alone, 3,128 individuals
would be reclassified from low or intermediate risk (i.e., <10%) to high risk (i.e.,�10%), and
3,405 individuals would be reclassified from high risk to low or intermediate risk, of whom
approximately 358 and 271 would be expected to have a CVD event within 10 years, respec-
tively (S11 Table; S13 Fig), suggesting the need to screen 5,747 people with additional assess-
ment of PRSs to help prevent 1 additional event over 10 years.
Discussion
We conducted complementary analyses in UKB, a purpose-designed prospective study of
about 500,000 individuals, and the CPRD, a cohort of 2.1 million people derived from an
extract of contemporary computerised records from general practices in the UK. Overall, our
results suggest that the addition of PRSs to conventional risk factors can provide modest
improvement in prediction of first-onset CVD, which, if applied at scale, could help prevent
7% more CVD events than use of conventional risk factors alone. Our results have potential
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implications for CVD risk prediction and for the evaluation of the potential population health
utility of PRSs for disease.
First, our modelling suggests that, if applied to the contemporary UK population aged 40–
75 years [38], additional use of PRSs could help prevent at least several thousand CVD events
over the next 10 years beyond assessment of conventional risk factors alone.
Fig 5. Estimated public health impact with targeted assessment of polygenic risk scores among 100,000 UK adults in a primary care setting.
CVD, cardiovascular disease; LDL, low-density lipoprotein; PRS, polygenic risk score.
https://doi.org/10.1371/journal.pmed.1003498.g005
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Second, our results suggest that targeted use of PRSs would be almost 15 times more effi-
cient than blanket population-wide use. In a modelled scenario in which PRSs were assessed in
a primary care setting only among individuals considered at intermediate CVD risk after ini-
tial screening with conventional risk predictors alone, we estimated that such targeted assess-
ment of PRSs could reclassify approximately 12% of screened individuals to the high-risk
category, of whom 11% would be expected to have a CVD event within 10 years. If such a tar-
geted approach were to be coupled with initiation of statin therapy in accordance with guide-
lines, our data suggest 1 extra CVD outcome could be prevented over a period of 10 years
for approximately every 340 people in whom PRSs are assessed (compared with the need to
screen approximately 5,700 people to achieve the same gain when using a blanket screening
approach).
Third, as a benchmark, we compared the incremental predictive gains afforded by assess-
ment of PRSs with those provided by CRP measurement (a plasma biomarker recommended
for screening in some primary prevention guidelines) [12,15], with our results demonstrating
a>1.5-fold greater gain in predictive accuracy with PRSs than CRP.
Fourth, we found that assessment of PRSs could improve prediction of CHD much more
than prediction of stroke. Further work is needed to understand fully the reasons for such dif-
ferential gains, which may relate both to the greater phenotypic heterogeneity of stroke out-
comes [39–41] and the relatively lower statistical power of previous GWASs of stroke [24,41]
compared with CHD [23]. It is likely that the composite outcome of CVD involves greater phe-
notypic and genetic heterogeneity than either CHD or stroke alone. Nevertheless, our study
used the primary outcome of any first CVD event (defined as fatal or nonfatal CHD or stroke),
in keeping with current CVD primary prevention guidelines that promote joint prediction
and prevention of CHD and stroke.
Our study had major strengths. In the analysis of UKB, we approximated the targeted popu-
lation for CVD primary prevention efforts by focusing on>300,000 participants without a his-
tory of CVD at baseline who were not taking lipid-lowering treatment. For these participants,
we had access to concomitant and nearly complete information on several conventional CVD
risk factors (e.g., lipid measurements) as well as on PRSs. We used multiple complementary
metrics of risk discrimination and reclassification, as well as different absolute risk thresholds
used in different clinical guidelines. The broadly concordant results we observed across these
metrics supported the validity of our main conclusions. To extend the relevance of our find-
ings to a UK primary care population, we also conducted modelling using the UK CPRD,
adapting (recalibrating) our findings from UKB to be more representative of the general popu-
lation. This adaptation was important because the general UK population has a higher baseline
risk for CVD than the volunteers who enrolled in UKB, underscoring the need for recalibra-
tion when using established risk thresholds, and before making judgements about the popula-
tion health utility of PRSs.
Our study also had limitations. We studied only middle-aged European ancestry partici-
pants in the UK, which limits the generalisability of our results. Hence, we (and others) are
now addressing this gap by conducting studies of PRSs for CVD in different ethnic groups, as
well as in other countries. Our study also lacked a health economic evaluation, which was
beyond the scope of present analysis. We acknowledge the importance of health economic
evaluations as part of future considerations to assess the clinical utility of PRSs for CVD pre-
vention, noting that genome-wide array genotyping has a one-time cost (approximately £25 at
current prices in the UK) and can be used to calculate PRSs for CVD as well as for many other
chronic diseases. In particular, future studies (including health economic evaluations) are
needed to evaluate a range of different CVD screening strategies, including a ‘genome first’
approach that inverts the current ‘conventional risk factors first’ approach to CVDs.
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Our study did not assess potential psychological harms of using genetic information in
CVD risk prediction. However, a previous randomised trial has excluded material effects of
this type [42]. We used a conventional 10-year timeframe and standard clinical risk categories,
acknowledging that reclassification analyses are intrinsically sensitive to choices of follow-up
interval and clinical risk categories. Although we used 9-year risk estimates in reclassification
analyses because 10 years of follow-up was not available for all UKB recruitment centres, it had
minimal influence on our results. Somewhat greater population health impact than suggested
by our analysis would be estimated if we had used less conservative modelling assumptions
(e.g., more effective statin regimens, longer time horizons), conventional risk factor weights
that were not fitted to UKB, or alternative disease outcomes (e.g., an exclusive focus on CHD).
Conversely, our models could have overestimated the potential benefits of assessing PRSs
because not all people eligible for statins will receive them or be willing and able to take them
and adherent.
In conclusion, our results suggest that the addition of PRSs to conventional risk factors can
modestly enhance the prediction of first-onset CVD and could translate into population health




S1 Fig. Exclusion criteria applied in derivation of the primary analytic dataset. �Prior his-
tory of cardiovascular disease at baseline included coronary heart disease, angina, other heart
disease, stroke, transient ischaemic attack, peripheral vascular disease, and cardiac revasculari-
sations.
(TIF)
S2 Fig. Hazard ratios for coronary heart disease, stroke, and the composite cardiovascular
disease outcome (including coronary heart disease, stroke, and cardiac revascularisations),
adjusted for conventional risk factors. Hazard ratios (HRs) were estimated using Cox regres-
sion, stratified by study centre and sex, and adjusted for age at baseline, smoking status, history
of diabetes, systolic blood pressure, total cholesterol, and HDL cholesterol, where appropriate.
For continuous variables, HRs are shown for each SD higher of each predictor to facilitate
comparison. For categorical variables, HRs are shown for men versus women, for patients
with diabetes versus without, and for current smokers versus others.
(TIFF)
S3 Fig. Shape and strength of associations of polygenic risk scores with risk of coronary
heart disease and stroke. The shape of association was estimated by dividing all participants
into fifths. Hazard ratios were estimated using Cox regression, stratified by study centre and
sex, and adjusted for age at baseline. Each square has an area inversely proportional to the
effective variance of the log risk in that specific group, with vertical lines representing the 95%
confidence intervals.
(TIFF)
S4 Fig. Hazard ratios of polygenic risk scores (PRSs) for coronary heart disease and stroke,
after progressive adjustment for conventional cardiovascular risk factors. Hazard ratios
were estimated using Cox regression, stratified by study centre and sex, and adjusted for con-
ventional cardiovascular risk factors, where appropriate.
(TIFF)
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S5 Fig. Adjusted hazard ratios of polygenic risk scores for incident coronary heart disease
and stroke by population characteristics at baseline. Hazard ratios were estimated using Cox
regression, stratified by study centre and sex, and adjusted for conventional cardiovascular
risk factors, where appropriate.
(TIFF)
S6 Fig. Observed and predicted cardiovascular risk when adding information on poly-
genic risk scores and/or C-reactive protein to conventional risk factors, in UK Biobank.
PRS, polygenic risk score; CRP, C-reactive protein; RMSE, root mean square error; GND
Chi-sq, Greenwood–Nam–D’Agostino chi-squared index. Conventional risk factors
included age at baseline, sex, smoking status, history of diabetes, systolic blood pressure,
total cholesterol, and HDL cholesterol levels. Polygenic risk scores included the polygenic
risk score for coronary heart disease and the one for ischaemic stroke (see Fig 2) as 2 linear
predictors in the model throughout. To avoid optimism in assessing calibration of the mod-
els, we applied a 10-fold cross-validation approach. We divided the datasets into 10 random
subsets with the same number of participants, with prediction models developed within
90% of the dataset, and validated using the remaining 10% of the dataset. Each blue square
in the plots represents the mean value of the predicted/observed risk within each decile;
these values were pooled across the 10 validation subsets and weighted by the number of
events in that group. The ratios were calculated as the ratio of observed risks to predicted
risks, with 1 representing perfect calibration. The RMSE was used to assess the differences
between the predicted risks and the observed risks. The Greenwood–Nam–D’Agostino test
is an extension of the Hosmer–Lemeshow test to situations with censored survival data, and
tests the null hypothesis that the observed and expected probabilities are identical in each
group.
(TIFF)
S7 Fig. Incremental predictive ability of polygenic risk scores (PRSs) for cardiovascular
disease, above conventional risk factors. Conventional risk factors included age at baseline,
sex, smoking status, history of diabetes, and systolic blood pressure, with or without baseline
measurements of total cholesterol and HDL cholesterol.
(TIFF)
S8 Fig. Incremental predictive values of polygenic risk scores (PRSs), above conventional
risk factors, including body-mass index or family history of cardiovascular disease in the
reference model. CVD, cardiovascular disease. Conventional risk factors included age at base-
line, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and
HDL cholesterol. Polygenic risk scores included the polygenic risk score for CHD and the one
for ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout.
(TIFF)
S9 Fig. Incremental predictive values of polygenic risk scores (PRSs) above conventional
risk factors, among individuals with or without lipid-lowering treatment, and for different
cardiovascular outcomes. Conventional risk factors included age at baseline, sex, smoking
status, history of diabetes, systolic blood pressure, total cholesterol, and HDL cholesterol. Poly-
genic risk scores included the polygenic risk score for coronary heart disease and the one for
ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout. Cardiac procedures
included cardiovascular outcomes identified via OPCS-4: K40–K46, K49, K50.1, K50.2, K50.4,
or K75.
(TIFF)
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S10 Fig. Incremental predictive value of polygenic risk scores, above conventional risk fac-
tors, by 10-fold cross-validation in UK Biobank. Polygenic risk scores included the polygenic
risk score for CHD and the one for ischaemic stroke (see Fig 2) as 2 linear predictors in the
model throughout. Each subset represented a 10% randomly selected subset of UK Biobank
participants from the entire study population. The prediction model was derived using 90% of
the dataset, and validated among the remaining 10%. The overall C-index and relevant changes
were estimated by meta-analysing the subset-specific results, weighted by the number of events
in that subset.
(TIFF)
S11 Fig. Incremental predictive value of polygenic risk scores, above conventional risk fac-
tors, when leaving 1 recruitment centre out per iteration in UK Biobank.
(TIFF)
S12 Fig. Estimates of public health impact with targeted assessment of polygenic risk
scores, among 100,000 UK adults using American Heart Association/American College of
Cardiology guideline.
(DOCX)
S13 Fig. Estimates of public health impact of additional assessment of polygenic risk scores
or C-reactive protein, above conventional risk factors, among 100,000 individuals. Num-
bers in red are shown for individuals who were initially classified as being at high risk and
were reclassified down to intermediate risk; numbers in blue are shown for individuals moving
from intermediate risk to high risk. Among 100,000 individuals, 1,197 cases and 7,354 non-
cases were treated, irrespective of their 10-year CVD risk, since they had history of diabetes or
LDL cholesterol� 5.0 mmol/l. The number of cases screened as high risk, or classified as high
risk due to diabetes or LDL cholesterol level, using conventional risk factors alone was 5,054,
and thus, the number of events prevented was 1,011 (5,054 × 0.2).
(TIF)
S1 Table. Definition of study outcomes.
(DOCX)
S2 Table. Incremental predictive ability of polygenic risk scores, and C-reactive protein,
above conventional risk factors, by population characteristics at baseline. Conventional
risk factors included age at baseline, sex, smoking status, history of diabetes, systolic blood
pressure, total cholesterol, and HDL cholesterol. Prediction model was developed using Cox
regression for all participants, stratified by study centre and sex, adjusted for conventional risk
predictors, where appropriate. Polygenic risk scores included the polygenic risk score for CHD
and the one for ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout.
(DOCX)
S3 Table. Net reclassification index (NRI) for incident cardiovascular disease by addition
of information on polygenic risk scores, and C-reactive protein, above conventional risk
factors, for non-cases and cases. ACC, American College of Cardiology; AHA, American
Heart Association; NICE, National Institute for Health and Care Excellence. �Conventional
risk factors included age, sex, smoking, systolic blood pressure, history of diabetes, total choles-
terol, and HDL cholesterol. Polygenic risk scores included the polygenic risk score for CHD
and the one for ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout.
Calculations of the above categorical NRIs were <5%, 5% to<7.5%, and�7.5% according to
the 2019 ACC/AHA guideline, and <5%, 5% to<10%, and�10% according to the 2014 NICE
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guideline.
(DOCX)
S4 Table. Partial likelihood ratio test for models with polygenic risk scores beyond conven-
tional risk factors, C-reactive protein, and treatment of hypertension. Conventional risk
factors included age at baseline, sex, smoking status, history of diabetes, systolic blood pres-
sure, total cholesterol, and HDL cholesterol, with stratification by study centre and sex, where
appropriate.
(DOCX)
S5 Table. Net reclassification index (NRI) for incident cardiovascular disease by addition
of information on polygenic risk scores, and C-reactive protein, above conventional risk
factors, for non-cases and cases, including participants on statin treatment at baseline.
ACC, American College of Cardiology; AHA, American Heart Association; NICE, National
Institute for Health and Care Excellence. �Conventional risk factors included age, sex, smok-
ing, systolic blood pressure, history of diabetes, total cholesterol, and HDL cholesterol. Poly-
genic risk scores included the polygenic risk score for CHD and the one for ischaemic stroke
(see Fig 2) as 2 linear predictors in the model throughout. Calculations of the above categorical
NRIs were<5%, 5% to<7.5%, and�7.5% according to the 2019 ACC/AHA guideline, and
<5%, 5% to<10%, and�10% according to the 2014 NICE guideline.
(DOCX)
S6 Table. Comparison of different polygenic risk scores (PRSs) on strength of associations,
discriminative ability, and reclassification index for different cardiovascular outcomes, in
UK Biobank. CVD, cardiovascular disease; CHD, coronary heart disease; IS, ischaemic stroke;
CI, confidence interval. Conventional risk factors included age at baseline, sex, smoking status,
history of diabetes, systolic blood pressure, total cholesterol, and HDL cholesterol, with stratifi-
cation by study centre and sex, where appropriate. The PRS for CHD and the PRS for IS were
constructed using methods as in our previous work [1]. The PRS for stroke was constructed
using the genome-wide significant variants in the MEGASTROKE consortium for total stroke,
and linkage-disequilibrium-thinned in UK Biobank, with corresponding weights taken from
the MEGASTROKE consortium [2]. Construction procedures of the 2 above PRSs did not
include estimates from previous GWASs on other vascular risk factors. The PRS for IS was con-
structed using methods described in our previous work [3], by taking account of 19 phenotypes,
and is publicly available (https://www.pgscatalog.org/score/PGS000039/). The PRS for CVD
was constructed using the same approach as the PRS for IS but with CVD as the outcome.
(DOCX)
S7 Table. Incremental predictive ability of polygenic risk scores, and C-reactive protein,
above the updated Pooled Cohort Equations (PCE) score. �The PCE score for study partici-
pants in UK Biobank was calculated using the updated Pooled Cohort Equations score, i.e., the
weights for each constituent predictor variable, as previously published [1]. ��PCE variables
included age at baseline, sex, smoking status, history of diabetes, systolic blood pressure, total
cholesterol, HDL cholesterol, ethnicity, and treatment of high blood pressure, weighted by the
Cox regression coefficients estimated in UK Biobank. Polygenic risk scores included the poly-
genic risk score for CHD and the one for ischaemic stroke (see Fig 2) as 2 linear predictors in
the model throughout.
(DOCX)
S8 Table. Incremental predictive ability of polygenic risk scores, and C-reactive protein,
with or without adjusting for competing risk from non-cardiovascular death. Conventional
PLOS MEDICINE Polygenic risk scores in cardiovascular disease prediction
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003498 January 14, 2021 17 / 22
risk factors included age at baseline, sex, smoking status, history of diabetes, systolic blood
pressure, total cholesterol, and HDL cholesterol. Polygenic risk scores included the polygenic
risk score for CHD and the one for ischaemic stroke (see Fig 2) as 2 linear predictors in the
model throughout. Cumulative incidence of the composite CVD outcomes was estimated
using the cause-specific hazards ratios from Cox regression, in the presence of competing risk
from non-CVD deaths.
(DOCX)
S9 Table. Estimates of public health impact with targeted assessment (intermediate risk:
5% to <10%) of polygenic risk scores, and C-reactive protein, among 100,000 UK adults.
PRS, polygenic risk score; CRP, C-reactive protein. Conventional risk factors included age at
baseline, sex, smoking, systolic blood pressure, history of diabetes, total cholesterol, and HDL
cholesterol. Polygenic risk scores included the polygenic risk score for CHD and the one for
ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout. The predicted
10-year cardiovascular risk categories used the 2014 NICE guideline. Estimates of public health
impact for a hypothetical population of 100,000 individuals (40–75 years) were based on (1)
the sex- and age-specific (5-year) profile of a standard UK population (2017 mid-year popula-
tion) [35] and (2) sex-specific 5-year age-at-risk incidence rates of cardiovascular disease in
the CPRD, among individuals without prior history of cardiovascular disease and not on statin
treatment at baseline. Estimates for public health impact are shown before and after recalibra-
tion.
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S10 Table. Estimates of public health impact with targeted assessment (intermediate risk:
5% to <7.5%) of polygenic risk scores (PRSs), and C-reactive protein, among 100,000 UK
adults. CRP, C-reactive protein. Conventional risk factors included age at baseline, sex, smok-
ing, systolic blood pressure, history of diabetes, total cholesterol, and HDL cholesterol. Poly-
genic risk scores included the polygenic risk score for CHD and the one for ischaemic stroke
(see Fig 2) as 2 linear predictors in the model throughout. The predicted 10-year cardiovascu-
lar risk categories used the 2019 American Heart Association/American College of Cardiology
guideline. Estimates of public health impact for a hypothetical population of 100,000 individu-
als (40–75 years) were based on (1) the sex- and age-specific (5-year) profile of a standard UK
population (2017 mid-year population) [35] and (2) sex-specific 5-year age-at-risk incidence
rates of cardiovascular disease in the CPRD, among individuals without prior history of car-
diovascular disease and not on statin treatment at baseline. Estimates for public health impact
are shown before and after recalibration.
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S11 Table. Numerical results for estimates of public health impact by additional assess-
ment of polygenic risk scores (PRSs) or C-reactive protein, above conventional risk predic-
tors, among 100,000 individuals. �Among cases and non-cases, respectively, 1,197 and 7,354
participants had diabetes or LDL cholesterol measurement of 5.0 mmol/l or greater. Numbers
in red are shown for individuals who were reclassified downwards with additional assessment,
and numbers in blue are shown for individuals who were reclassified upwards with additional
assessment. Polygenic risk scores included the polygenic risk score for CHD and the one for
ischaemic stroke (see Fig 2) as 2 linear predictors in the model throughout.
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25. Wünnemann F, Lo KS, Langford-Avelar A, Busseuil D, Dubé M-P, Tardif J-C, et al. Validation of
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